Example: Heart Attack

Clinical Trials on Glabellar Crease

Total 10000 results

NCT05252988

Active, not recruiting

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib (DIANER)

HER2 Positive Breast Cancer | Hormone Receptor Positive | Early-stage Breast Cancer
NCT01672684

Completed

Phase I: At-Home Support for Rural Women Using Group Video Calling

Depression | Post-traumatic Stress Disorder | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
NCT06058377

Recruiting

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma
NCT05488145

Terminated

A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma | HER2-Negative Breast Carcinoma
NCT02824575

Terminated

Rebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast Cancer

Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Carcinoma | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Breast Adenocarcinoma
NCT03238703

Withdrawn

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Stage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | Postmenopausal
NCT07107594

Recruiting

Multimodal Prehabilitation Program That Combines Physical Exercise, Psychological Intervention and Nutritional Support to Improve the Response to Neoadjuvant Chemoterhapy in Early Breast Cancer Patients (DIANA)

Prehabilitation | Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT06817525

Recruiting

Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC

Triple-negative Breast Cancer
NCT06777420

Recruiting

Question Prompt List in Breast Cancer Patients Planned for Neoadjuvant Chemotherapy (QPL)

Neoadjuvant Therapy | Shared Decision Making | Breast Cancer Early Stage Breast Cancer (Stage 1-3)
NCT04738292

Terminated

Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4/6 Inhibitors (The SMILE Study)

Metastatic Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer
NCT01922921

Completed

Vaccine Therapy With or Without Polysaccharide-K in Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy

Stage IV Breast Cancer | Recurrent Breast Carcinoma | HER2/Neu Positive
NCT06763328

Recruiting

Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Invasive Breast Carcinoma
NCT02620852

Recruiting

Women Informed to Screen Depending on Measures of Risk (Wisdom Study) (WISDOM)

Breast Cancer | Breast Cancer Screening | Breast Carcinoma in Situ
NCT04088435

Terminated

Xoft® Intraoperative Radiotherapy (IORT) for Patients With Early-Stage Breast Cancer

Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage IIA | Breast Cancer, Invasive Ductal | Invasive Mammary Carcinoma
NCT07346339

Completed

Sensory Mindfulness for NICU Mothers: Effects on Breast Milk, Well-Being, and Stress

Well-being | Newborn Diseases | Breast Milk Collection | MİNDFULNESS
NCT03020888

Completed

Magseed Magnetic Marker Localization

Breast Lesions | Disorders of Breast
NCT06184750

Recruiting

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast Carcinoma | Breast Atypical Ductal Hyperplasia | Breast Atypical Lobular Hyperplasia | Breast Ductal Carcinoma In Situ | Breast Lobular Carcinoma In Situ | Estrogen Receptor-Positive Breast Carcinoma
NCT02411656

Active, not recruiting

Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy

Edema | Erythema | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Recurrent Inflammatory Breast Carcinoma | Stage IV Inflammatory Breast Carcinoma | Peau d'Orange
NCT06106282

Completed

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage 0 Breast Cancer AJCC v8 | Hormone Receptor-Positive Breast Carcinoma
NCT05760612

Recruiting

Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Neoadjuvant Trastuzumab Plus Pertuzumab

HER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | Neratini
NCT04692831

Active, not recruiting

Testing a New Imaging Agent to Identify Cancer

HER2-positive Metastatic Breast Cancer | HER-2 Protein Overexpression | HER-2 Positive Malignant Carcinoma of Breast
NCT04137744

Completed

Axillary Reverse Mapping Using Methylene Blue Subcutaneous Injection Can Identify Arm Lymph Nodes and Vessels, Measuring Arm Size for Lymphedema, Histopathological Examination of Arm Lymph Nodes Included With Axillary Lymph Node Dissection

Early Breast Cancer | Arm Lymphedema | Lymphatic Spread of Breast Cancer
NCT00509587

Completed

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer
NCT02057432

Completed

Image-guided Breast Surgery in the Advanced Multimodality Image Guided Operating Suite (AMIGO)

Stage I Breast Carcinoma | Stage II Breast Carcinoma
NCT07131592

Recruiting

Effect of Intravenous and Topical Tranexamic Acid on Drain Output in Breast Reduction Surgery

Breast Reductions | Drain Output After Breast Reduction Surgery
NCT05235412

Completed

A Cohort Study on Milk Composition, Health Outcomes, and Feeding Practices of Chinese Mothers and Infants (Phoenix)

Breast Feeding | Breast Milk Expression
NCT06216106

Completed

Data Collection of Prepectoral Breast Reconstruction With Polyurethane Implantes (IBR-PPBR)

Breast Reconstruction | Radiation Therapy Complication | Prepectoral Breast Reconstruction
NCT07543536

Not yet recruiting

Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer (MEGA-TACT-BC3)

Advanced/Metastatic Breast Cancer | HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
NCT07244874

Not yet recruiting

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

TNBC - Triple-Negative Breast Cancer | PD-L1 Positive
NCT07153965

Not yet recruiting

Sacituzumab Tirumotecan Plus Tagitanlimab in Previously Treated Locally Advanced or Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC) | PD-L1 Positive
NCT07114679

Not yet recruiting

Molecular Breast Imaging (MBI)-Guided Biopsy (MBI-GB-Pilot)

Breast Neoplasm | Biopsy | Molecular Imaging | Dense Breasts | Breast Cancer Detection
NCT06653972

Not yet recruiting

Efficacy and Safety of a Two-week Dosing Regimen of Vinorelbine Combined with Liposomal Doxorubicin in the Treatment of HER2-negative Advanced Breast Cancer (EASOVCWDITHABC)

Vinorelbine | Liposomal Doxorubicin | Her2-negative Metastatic Breast Cancer
NCT06278870

Recruiting

Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial

First-line Treatment | HER2-positive Metastatic Breast Cancer
NCT06151249

Not yet recruiting

Evaluate the Meritup Oral Solution to Decrease Fatigue in Metastatic Breast Cancer Patients Receiving Chemotherapy

Metastatic Breast Cancer
NCT05955170

Recruiting

Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer (TUC-TOC)

HER2-positive Breast Cancer
NCT05904964

Recruiting

Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)

HR Positive/HER2 Low Expression Metastatic Breast Cancer
NCT05901428

Recruiting

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer
NCT05878314

Recruiting

Impact of Endocrine Therapy, Menstrual Cycle, PAM50, Ki67 on Treatment Decisions in HR+ and HER2- Breast Cancer

Hormone Receptor Positive HER-2 Negative Breast Cancer
NCT05600153

Not yet recruiting

Axillary Versus Primary Breast Approach for Second-stage Breast Reconstruction (AvBSR)

Breast Neoplasm Female | Breast Reconstruction | Wound Complication
NCT05490433

Recruiting

Robot-assisted vs. Open Nipple-sparing Mastectomy With Immediate Breast Reconstruction (ROM)

Breast Cancer Classified as TNM Stage 0-IIIa
NCT05301790

Not yet recruiting

Breast MRI in Evaluation of Pathologic Response in Patients With Breast Cancer With Neoadjuvent Chemotherapy

Role of MRI in Evaluation of Breast Cancer
NCT05286437

Recruiting

Phase II Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer With Letrozole (LaPemERLA)

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer
NCT05263882

Not yet recruiting

Gemcitabine Combined With Eribulin Regimen in the Treatment of Second-line Above Recurrent HER2-negative Breast Cancer

HER2-negative Breast Cancer
NCT05232006

Not yet recruiting

PARP-inhibitor on Advanced Metastatic Breast Cancer in Germline PALB2 Mutations Carriers (PALB2-PARPi-01)

Metastatic Breast Cancer in Germline-PALB2 Mutations Carriers
NCT06172127

Active, not recruiting

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer (DEMETHER)

HER2-positive Breast Cancer
NCT02514681

Completed

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer (PRECIOUS)

HER2-positive Locally Advanced or Metastatic Breast Cancer
NCT03032406

Active, not recruiting

CLEVER Pilot Trial: A Phase II Pilot Trial of HydroxyChLoroquine, EVErolimus or the Combination for Prevention of Recurrent Breast Cancer

Breast Cancer Stage IIB
NCT03460067

Active, not recruiting

Omission of Radiation in Patients With Her-2 Positive Breast Cancer

HER2-positive Breast Cancer
NCT04781959

Completed

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Early-stage Breast Cancer
NCT03644186

Completed

To Reduce the Use of Chemotherapy in Postmenopausal Patients With ER-positive and HER2-positive Breast Cancer (TOUCH) (TOUCH)

Breast Cancer | HER2-positive Breast Cancer | Estrogen Receptor Positive Tumor

Clinical Trials on Glabellar Crease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations